The vascular smooth muscle cell: a therapeutic target in Type 2 diabetes? (Q38103313)

28 August 2017

The vascular smooth muscle cell: a therapeutic target in Type 2 diabetes? (English)

1 reference

28 August 2017

1 reference

Kirsten Riches

2

0 references

Karen E Porter

series ordinal

1

object named as

Karen E Porter

0 references

language of work or name

English

0 references

publication date

1 August 2013

1 reference

PubMed ID

23634936

full work available at URL

28 August 2017

http://eprints.whiterose.ac.uk/77133/

content deliverer

White Rose Research Online

0 references

1 reference

28 August 2017

125

1 reference

28 August 2017

167-182

1 reference

28 August 2017

4

1 reference

Early vascular aging (EVA): consequences and prevention

28 August 2017

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

NF-κB, inflammation, and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Diabetes and aging: epidemiologic overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

The diabetic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Intensive glycemic control and cardiovascular disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Diabetes and coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Diabetes impairs arteriogenesis in the peripheral circulation: review of molecular mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Inflammation and thrombosis in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Card

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Cardiovascular disease in diabetes: where does glucose fit in?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Molecular regulation of vascular smooth muscle cell differentiation in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Smooth muscle cell phenotypic switching in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Smooth muscle phenotypic modulation is an early event in aortic aneurysms

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Vascular cell senescence: contribution to atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Smooth muscle 22 alpha maintains the differentiated phenotype of vascular smooth muscle cells by inducing filamentous actin bundling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

PIAS1 mediates TGFbeta-induced SM alpha-actin gene expression through inhibition of KLF4 function-expression by protein sumoylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNA regulation of cardiovascular development

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Can microRNAs control vascular smooth muscle phenotypic modulation and the response to injury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

miR-10a contributes to retinoid acid-induced smooth muscle cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNA-1 regulates smooth muscle cell differentiation by repressing Kruppel-like factor 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

SMAD proteins control DROSHA-mediated microRNA maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Bone morphogenetic protein 4 promotes vascular smooth muscle contractility by activating microRNA-21 (miR-21), which down-regulates expression of family of dedicator of cytokinesis (DOCK) proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Molecular basis for antagonism between PDGF and the TGFbeta family of signalling pathways by control of miR-24 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Pervasive roles of microRNAs in cardiovascular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Enhanced cell cycle entry and mitogen-activated protein kinase-signaling and downregulation of matrix metalloproteinase-1 and -3 in human diabetic arterial vasculature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Smooth muscle cells cultured from human saphenous vein exhibit increased proliferation, invasion, and mitogen-activated protein kinase activation in vitro compared with paired internal mammary artery cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Influence of type 2 diabetes on functional and structural properties of coronary artery bypass conduits

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Comparing the mechanical influence of vinculin, focal adhesion kinase and p53 in mouse embryonic fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Chromosomal telomere attrition as a mechanism for the increased risk of epithelial cancers and senescent phenotypes in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Effect of insulin on growth of cultured human arterial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Insulin Affects Vascular Smooth Muscle Cell Phenotype and Migration Via Distinct Signaling Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappaB activation in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Human proinsulin C-peptide prevents proliferation of rat aortic smooth muscle cells cultured in high-glucose conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Aspirin resistance and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Role of advanced glycation end products in cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

RAGE and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Decreased neointimal extracellular matrix formation in RAGE-knockout mice after microvascular denudation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Negative feedback regulation between microRNA let-7g and the oxLDL receptor LOX-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Phenotype switch of vascular smooth muscle cells after siRNA silencing of filamin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Oleic acid induces smooth muscle foam cell formation and enhances atherosclerotic lesion development via CD36.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Fatty acids induce apoptosis in human smooth muscle cells depending on chain length, saturation, and duration of exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Palmitate promotes the paracrine effects of macrophages on vascular smooth muscle cells: the role of bone morphogenetic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Oleic acid and adipokines synergize in inducing proliferation and inflammatory signalling in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

7-Ketocholesterol and cholesterol-5alpha,6alpha-epoxide induce smooth muscle cell migration and proliferation through the epidermal growth factor receptor/phosphoinositide 3-kinase/Akt signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Inflammation: the link between insulin resistance, obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing alpha5beta1 integrin expression and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Epigenetic mechanisms in diabetic vascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Influence of the mutation "diabetes" on insulin release and islet morphology in mice of different genetic backgrounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Elevated Ca2+ sparklet activity during acute hyperglycemia and diabetes in cerebral arterial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Calcium homeostasis in vascular smooth muscle cells is altered in type 2 diabetes by Bcl-2 protein modulation of InsP3R calcium release channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Altered clock gene expression and vascular smooth muscle diurnal contractile variations in type 2 diabetic db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

COX-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Increased neointimal formation after surgical vein grafting in a murine model of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Enhanced proatherogenic responses in macrophages and vascular smooth muscle cells derived from diabetic db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

The AGE-breaker ALT-711 restores high blood flow-dependent remodeling in mesenteric resistance arteries in a rat model of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MKP-1 expression and stabilization and cGK Ialpha prevent diabetes- associated abnormalities in VSMC migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Inhibition of cell cycle progression and migration of vascular smooth muscle cells by prostaglandin D2 synthase: resistance in diabetic Goto-Kakizaki rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Enhancement of interleukin-1beta-induced iNOS expression in cultured vascular smooth muscle cells of Goto-Kakizaki diabetes rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

A minipig model of high-fat/high-sucrose diet-induced diabetes and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Metabolic memory: implications for diabetic vascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Intervention at the very early stage of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Statins and vein graft failure in coronary bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Nuclear factor of activated T cells 5 regulates vascular smooth muscle cell phenotypic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Insulin-mediated upregulation of K(Ca)3.1 channels promotes cell migration and proliferation in rat vascular smooth muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Biomarkers for the prediction of type 2 diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Biomarkers of atherosclerotic plaque instability and rupture

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

miRNAs: roles and clinical applications in vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

The involvement of microRNAs in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNAs in diabetes: tiny players in big disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Pro-inflammatory role of microrna-200 in vascular smooth muscle cells from diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Therapeutic advances in MicroRNA targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

MicroRNAs as therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Vascular smooth muscle cell phenotypic plasticity: focus on chromatin remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Epigenetic modifications in cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Cardiovascular epigenetics: from DNA methylation to microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Epigenetics: deciphering its role in diabetes and its chronic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Epigenetic phenomena linked to diabetic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Moving AHEAD with an international human epigenome project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

The role of epigenetics in the pathology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

Prevention Conference VI: Diabetes and Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120413

21 January 2018

Identifiers

DOI

10.1042/CS20120413

1 reference

release_j7sbghkhcrgmpo2xrisejjhqgi

28 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/j7sbghkhcrgmpo2xrisejjhqgi

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

23634936

1 reference